drugset / Trial / NCT00495729

15-Day Repeated-Dose Study With SB-649868 And Its Interaction With CYP3A4 Isoenzyme In Healthy Male Subjects.

NCT00495729

Phase 1 Completed 36 enrolled GlaxoSmithKline
RandomizedSingle-groupTreatment

Summary

Subjects will be screened within 28 days, Simvastatin dose and single SB-649868 dose 10 and 7 days prior to repeat dosing respectively, 15 days SB-649868 repeat dosing with safety and cognition function tests.

Timeline

Start
2007-04-18
Primary completion
2007-08-04
Completion
2007-08-04

Drugs

EvaluationDrugModalityDoseRoute
Subject SB-649868 Small molecule 5 mg Oral
Subject SB-649868 Small molecule 25 mg Oral
Subject Simvastatin Small molecule 10 mg Oral